To assess the effectiveness of liraglutide 3.0 mg in post-bariatric surgery patients, and to determine whether this would differ based on the type of bariatric surgery.
| INTRODUCTION
Bariatric surgery is considered the gold standard treatment for weight loss in patients with obesity and complications of obesity, based on superior long-term weight loss outcomes, and improvements in comorbidities compared to lifestyle and pharmaceutical interventions. 1 Despite the dramatic weight loss achieved with bariatric surgery (30%-45% weight loss 2 ), 10% to 20% of bariatric surgery patients will regain a significant amount of the weight they had lost, 3 which can be defined as a patient regaining 10% to 25% of excess weight or total weight lost. 4 Regardless, as greater number of patients have surgery, the concern of weight regain post-surgery has become significant.
In 2015, liraglutide 3.0 mg was approved for the treatment of excess weight in Canada. 5 In non-surgical populations, liraglutide 3.0 mg has been found to be associated with significant reductions in appetite and weight. 6 However, as surgical patients were excluded from phase III weight management pharmaceuticals trials, the effectiveness of liraglutide 3.0 mg in this population is unknown. Thus, the objective of the current study was to examine the weight loss associated with the use of liraglutide 3.0 mg in post-bariatric surgery patients. There was a total of 649 post-bariatric surgery patients referred to WMC for weight management and who consented for their data to be used for research. Of these, 174 patients were prescribed Over the 14.7 ± 24.0 months these patients attended the clinic, they lost 2.1 ± 9.0 kg (P > .05). The reason for not initiating liraglutide 3.0 mg was recorded for only six patients, and all stated it was due to cost. 
| METHODS

| WMC protocol
| Statistical analysis
Continuous variables are reported as mean ± SD and categorical variables as frequency (prevalence). Independent t test was undertaken to compare weight change between patients who did and did not achieve the recommended clinical dose of liraglutide 3.0 mg. One-way analysis of variance (ANOVA) was used to examine differences in age, body mass index (BMI), treatment time, percent changes in weight, and the side effect nausea and repeated measures ANOVA was used to examine absolute changes in weight based on the type of bariatric surgery patients had underwent. Least-square difference post-hoc was used where indicated. Differences in sex and the proportion of individuals achieving ≥5% and ≥10% weight loss based on the type of bariatric surgery were assessed using chi-square analysis. Changes in weight were compared in 2-month increments from 1-month postinitiation up to 1 year based on the type of bariatric surgery using proc mixed. Changes in weight loss were also compared using proc mixed for patients who were persistent on liraglutide 3.0 mg for ≤2 months, >2 to ≤4 months, and >4 months using proc mixed. All analyses were conducted using SAS version 9.4 (SAS Institute). A P-value ≤.05 was considered statistically significant.
| RESULTS
One hundred seventeen patients were included in the analysis.
Patients were primarily female (87.2%) and were 51.2 ± 9. Patients who had undergone RNYGB had a lower BMI prior to initiating liraglutide 3.0 mg than patients who had received a AGB or sleeve gastrectomy (P < .05, Table 1 lost a similar amount of weight whether or not they achieved the recommended maximum clinical dose (7.4 ± 6.9 vs 6.8 ± 11.4, P = .81).
A total of 92 side effects were reported among 59 of 117 patients (50.4%, Table 2 ). Gastrointestinal side effects were the most preva- Surgeries that remove a portion of the stomach (eg, RNYGB and gastric sleeve) are associated with increase in glucagon-like peptide-1 (GLP-1) levels, which have been thought to in part contribute to sustained weight loss post-surgery. 15, 16 Despite these well-known differences due to the type of bariatric surgery, few papers have examined the differences in weight loss by surgery type for those taking weight management pharmaceuticals. The studies which have primarily examined the use of phentermine, phentermine/topiramate, and naltrexone/bupropion, and report no differences for patients who had undergone RNYGB and AGB. However, individuals who had undergone gastric sleeve lost less weight than those who had undergone RNYGB and AGB. 13, 17 Consistent with previous literature, we did observe similar reductions in weight while taking liraglutide 3.0 mg for patients who had undergone RNYGB or AGB. This is surprising given GLP-1 levels are known to increase post-surgery in RNYGB patients but not in AGB patients, and as a GLP-1 analogue, liraglutide 3.0 mg temporarily increase the circulating levels of GLP-1 in the body. In contrast to previous research we did not observe less weight loss for patients who had had a gastric sleeve. In fact, patients had similar reductions in weight as of 1-month post-initiation of liraglutide 3.0 mg and up to 1 year regardless of the type of surgery they had.
Discrepancies in our findings may be due to differences in weight management pharmaceuticals or could be due to power issues given the relatively small number of patients who had undergone sleeve gastrectomy and had data on liraglutide 3.0 mg use for 1 year. Nonetheless, this may suggest that liraglutide 3.0 mg is especially beneficial for patients who have undergone gastric sleeve. As we are the first to study differences in weight loss by type of surgery for patients taking According to the liraglutide 3.0 mg monograph, gastrointestinal symptoms are prevalent side effects for patients who have not had bariatric surgery. 5 Consistent with the product monograph, 5 and research in post-bariatric surgery patients, 14 patients in the current study reported side effects that were primarily gastrointestinal in nature, with nausea being the most commonly reported side effect.
Overall, the medication appeared to be well tolerated, with only three patients reporting discontinuing due to adverse events (ie, two patients due to an allergic reaction, and one patient due to pancreatitis). Pancreatitis is a known potential side effect of liraglutide 3.0 mg and may occur in 0.1% to 0.3% of patients. 5 In the current study, the proportion was slightly higher but this could be attributed to our smaller sample size. Nonetheless, these results suggest that the side effects experienced by patients with bariatric surgery are similar to those reported in non-bariatric surgery patients taking liraglutide 3.0 mg and supports the notion that this medication may be a safe option to manage excess weight in post-bariatric surgery patients.
Our study has several strengths and limitations that warrant men- Current guidelines for the use of liraglutide for weight management recommend discontinuing treatment if the patient is unable to achieve a ≥5% weight loss after 16 weeks of use. 5, 18 As 47% (n = 55) of the patients in this study had taken liraglutide for 4 months or less, our sample may have included patients who are not responsive to liraglutide. Indeed, when patients who have taken liraglutide for 4 months or less are excluded, the proportion of patients who achieve clinically significant weight loss increases from 41.9% to 59.4%. Thus, the inclusion of these patients likely biased our results to the null. Our length of time of follow-up was variable, we could only verify that 10 of 53 patients had discontinued taking liraglutide 3.0 mg by 4 months.
In summary, in our centre, we found that post-bariatric surgery patients with insufficient weight loss or excessive weight regain who use liraglutide 3.0 mg were able to achieve a statistically significant weight loss, regardless of the type of bariatric surgery they had undergone. In addition, post-bariatric surgery patients taking liraglutide These results are promising as current methods for weight management in post-bariatric surgical patients are limited, and often have greater risks to the patient than the initial procedure itself. More research, using a more rigorous study design, is still necessary to determine the reproducibility of these results and whether certain weight management pharmaceuticals may be more efficacious for post-bariatric surgery patients than others.
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